Develops a one-time minimally invasive cryoablation device treating obesity as an alternative to bariatric surgery and GLP-1 drugs.
| Date | Round | Amount |
|---|---|---|
| May 2026 | Seed Sedivention (Magdeburg) raised 2.9M euros in a seed led by bmp Ventures and IBG to develop a one-time outpatient obesity treatment as an alternative to Ozempic. | $3.4M |
| Nov 2024 | Seed MedTech startup Sedivention raised EUR 800k from the High-Tech Gründerfonds to advance its obesity-therapy device. | $850K |